Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
ATRA | US
Overview
Corporate Details
- ISIN(s):
- US0465131078
- LEI:
- Country:
- United States of America
- Address:
- 1280 RANCHO CONEJO BLVD, 91320 THOUSAND OAKS
- Website:
- https://www.atarabio.com/
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company that develops off-the-shelf treatments for patients with cancer and autoimmune diseases. The company leverages its proprietary Epstein-Barr virus (EBV) T-cell platform and novel chimeric antigen receptor (CAR) technologies to create a pipeline of investigational therapies. Its allogeneic approach enables the manufacturing of T-cell therapies from healthy donors, which can be stored in inventory and rapidly delivered to patients. Atara is the first company to receive regulatory approval for an allogeneic T-cell immunotherapy, utilizing a scalable manufacturing process and a versatile platform with potential applications for a wide range of disease targets.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Atara Biotherapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Atara Biotherapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Atara Biotherapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
